Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 22

1.

Mipomersen, an apolipoprotein B synthesis inhibitor, lowers low-density lipoprotein cholesterol in high-risk statin-intolerant patients: a randomized, double-blind, placebo-controlled trial.

Visser ME, Wagener G, Baker BF, Geary RS, Donovan JM, Beuers UH, Nederveen AJ, Verheij J, Trip MD, Basart DC, Kastelein JJ, Stroes ES.

Eur Heart J. 2012 May;33(9):1142-9. doi: 10.1093/eurheartj/ehs023.

2.

Mipomersen: a safe and effective antisense therapy adjunct to statins in patients with hypercholesterolemia.

Ricotta DN, Frishman W.

Cardiol Rev. 2012 Mar-Apr;20(2):90-5. doi: 10.1097/CRD.0b013e31823424be. Review.

PMID:
22293857
3.

New LDL-cholesterol lowering therapies: pharmacology, clinical trials, and relevance to acute coronary syndromes.

Sahebkar A, Watts GF.

Clin Ther. 2013 Aug;35(8):1082-98. doi: 10.1016/j.clinthera.2013.06.019. Review.

PMID:
23932550
4.

Mipomersen and other therapies for the treatment of severe familial hypercholesterolemia.

Bell DA, Hooper AJ, Watts GF, Burnett JR.

Vasc Health Risk Manag. 2012;8:651-9. doi: 10.2147/VHRM.S28581. Review.

5.

Mipomersen is a promising therapy in the management of hypercholesterolemia: a meta-analysis of randomized controlled trials.

Li N, Li Q, Tian XQ, Qian HY, Yang YJ.

Am J Cardiovasc Drugs. 2014 Oct;14(5):367-76. doi: 10.1007/s40256-014-0077-0. Review.

PMID:
25027352
6.

Mipomersen, an antisense apolipoprotein B synthesis inhibitor.

Bell DA, Hooper AJ, Burnett JR.

Expert Opin Investig Drugs. 2011 Feb;20(2):265-72. doi: 10.1517/13543784.2011.547471. Review.

PMID:
21210756
7.

Mipomersen as a potential adjunctive therapy for hypercholesterolemia.

Patel N, Hegele RA.

Expert Opin Pharmacother. 2010 Oct;11(15):2569-72. doi: 10.1517/14656566.2010.512006. Review.

PMID:
20707601
8.

Managing the residual cardiovascular disease risk associated with HDL-cholesterol and triglycerides in statin-treated patients: a clinical update.

Reiner Z.

Nutr Metab Cardiovasc Dis. 2013 Sep;23(9):799-807. doi: 10.1016/j.numecd.2013.05.002. Review.

PMID:
23932901
9.

New therapies targeting apoB metabolism for high-risk patients with inherited dyslipidaemias: what can the clinician expect?

Sahebkar A, Watts GF.

Cardiovasc Drugs Ther. 2013 Dec;27(6):559-67. doi: 10.1007/s10557-013-6479-4. Review.

PMID:
23913122
10.

Safety and tolerability of injectable lipid-lowering drugs: a review of available clinical data.

Cicero AF, Tartagni E, Ertek S.

Expert Opin Drug Saf. 2014 Aug;13(8):1023-30. doi: 10.1517/14740338.2014.932348. Review.

PMID:
24961142
11.

Beyond statins: new lipid lowering strategies to reduce cardiovascular risk.

Noto D, Cefal├╣ AB, Averna MR.

Curr Atheroscler Rep. 2014 Jun;16(6):414. doi: 10.1007/s11883-014-0414-4. Review.

PMID:
24777633
12.

Mipomersen and lomitapide: Two new drugs for the treatment of homozygous familial hypercholesterolemia.

Gouni-Berthold I, Berthold HK.

Atheroscler Suppl. 2015 May;18:28-34. doi: 10.1016/j.atherosclerosissup.2015.02.005. Review.

PMID:
25936301
13.

Lomitapide and mipomersen: novel lipid-lowering agents for the management of familial hypercholesterolemia.

Dixon DL, Sisson EM, Butler M, Higbea A, Muoio B, Turner B.

J Cardiovasc Nurs. 2014 Sep-Oct;29(5):E7-E12. doi: 10.1097/JCN.0000000000000104. Review.

PMID:
24231894
14.

Statin intolerance: diagnosis and remedies.

Pirillo A, Catapano AL.

Curr Cardiol Rep. 2015 May;17(5):27. doi: 10.1007/s11886-015-0582-z. Review.

PMID:
25894795
15.

Investigational therapies for the treatment of atherosclerosis.

Tomkin GH, Owens D.

Expert Opin Investig Drugs. 2014 Oct;23(10):1411-21. doi: 10.1517/13543784.2014.922950. Review.

PMID:
24857672
16.

[ANMCO Position paper: Diagnostic and therapeutic pathways in patients with hypercholesterolemia and statin intolerance].

Gulizia MM, Colivicchi F, Arca M, Abrignani MG, Perna GP, Mureddu GF, Nardi F, Riccio C; ANMCO..

G Ital Cardiol (Rome). 2016 Jun;17(6):447-55. doi: 10.1714/2262.24348. Italian.

PMID:
27311087
17.

Clinical pharmacological properties of mipomersen (Kynamro), a second generation antisense inhibitor of apolipoprotein B.

Crooke ST, Geary RS.

Br J Clin Pharmacol. 2013 Aug;76(2):269-76. doi: 10.1111/j.1365-2125.2012.04469.x. Review.

18.

Mipomersen sodium: first global approval.

Hair P, Cameron F, McKeage K.

Drugs. 2013 Apr;73(5):487-93. doi: 10.1007/s40265-013-0042-2. Review.

PMID:
23564617
19.

Cholesterol Lowering Drugs.

Feingold KR, Grunfeld C.

In: De Groot LJ, Chrousos G, Dungan K, Feingold KR, Grossman A, Hershman JM, Koch C, Korbonits M, McLachlan R, New M, Purnell J, Rebar R, Singer F, Vinik A, editors. Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc.; 2000-.
2016 Aug 10.

20.
Items per page

Supplemental Content

Support Center